Prevail Therapeutics
Clinical trials sponsored by Prevail Therapeutics, explained in plain language.
-
One-Shot gene therapy tested in babies with devastating brain disease
Disease control OngoingThis study is testing a single-dose gene therapy called LY3884961 in infants with Type 2 Gaucher disease, a severe and fatal genetic disorder that damages the brain and body. The main goals are to see if the treatment is safe and if it can improve symptoms like movement and think…
Phase: PHASE1, PHASE2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
First human test of gene therapy for inherited dementia begins
Disease control OngoingThis is an early-stage study testing a new gene therapy called LY3884963 for people with a specific genetic form of frontotemporal dementia (FTD). The main goals are to check if the treatment is safe and to see if it can increase levels of a protective protein in the brain and sp…
Phase: PHASE1, PHASE2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
First-in-Human gene therapy injected into brain for Parkinson's
Disease control OngoingThis is an early-stage study testing a new gene therapy called LY3884961 for people with moderate to severe Parkinson's disease who have a specific genetic mutation (GBA1). The therapy is delivered via a single injection into the fluid around the brain and spinal cord. The main g…
Phase: PHASE1, PHASE2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC